FDA accepts for Priority Review Biologics License Application for ansuvimab as a treatment for Ebola

This investigational Ebola treatment is a monoclonal antibody isolated from a human survivor of the 1995 Ebola outbreak in Kikwit in the Democratic Republic of the Congo, who retained antibodies against Ebola 11 years after infection.


Biospace Inc.